<DOC>
	<DOCNO>NCT02567253</DOCNO>
	<brief_summary>The OvIP1 study design examine drug dose perfusion temperature affect pharmacokinetics pharmacodynamics cisplatin use ( hyperthermic ) intraperitoneal chemoperfusion , adjunct surgery , woman stage III epithelial ovarian cancer .</brief_summary>
	<brief_title>Intraoperative Intraperitoneal Chemoperfusion Treat Peritoneal Minimal Residual Disease Stage III Ovarian Cancer</brief_title>
	<detailed_description>Stage III ovarian cancer ( OC ) remain important cause cancer relate mortality woman . After successful initial treatment , patient eventually develop recurrent peritoneal disease arise peritoneal minimal residual disease ( pMRD ) leave primary cytoreductive surgery ( CRS ) . Intensification locoregional therapy intraoperative intraperitoneal chemoperfusion ( IPEC ) immediately follow CRS may prevent delay peritoneal recurrence . Although IPEC , usually hyperthermic condition , increasingly use OC , efficacy potential benefit hyperthermia present unknown.The primary aim study assess pharmacokinetic pharmacodynamic property IP cisplatin administer normothermic hyperthermic condition , different dose schedule . Additional endpoint include surgery related morbidity mortality , quality life , overall survival , disease free survival , peritoneal recurrence free survival , peritoneal cytology , exploration potential biomarkers .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Tumor type : * Biopsy proven serous epithelial ovarian carcinoma peritoneal carcinoma Primary recurrent disease Extent disease : Positive retroperitoneal lymph node /or microscopic metastasis beyond pelvis ( FIGO stage III , Appendix ( 47 ) ) Stage IV unilateral pleural fluid allow Complete nearly complete macroscopic cytoreduction time surgery ( CC0 CC1 ) deem possible base imaging , laparoscopy , Secondline patient ; platinum sensitive Age 18 year No major cardiac respiratory disease Absent limit ( &lt; 500ml ) clinical ascites Adequate performance status ( Karnofsky index &gt; 70 % ) Adequate mental faculty , allow understand propose treatment protocol provide inform consent Expected life expectancy 6 month Laboratory data : Serum creatinine ≤ 1.5 mg/dl calculate Glomerular Filtration Rate ( GFR ) ( CKDEPI ) ≥ 60 mL/min/1.73 m2 Serum total bilirubin ≤ 1.5 mg/dl , except know Gilbert 's disease Platelet count &gt; 100.000/µl Hemoglobin &gt; 9g/dl Neutrophil granulocyte &gt; 1.500/ml International Normalized Ratio ( INR ) ≤ 2 Absence alcohol and/or drug abuse No concurrent malignant disease No inclusion clinical trial interfere study protocol No concurrent chronic systemic immune hormone therapy , except neoadjuvant chemotherapy Absence severe organ insufficiency No pregnancy breast feed Written informed consent Severe uncontrolled cardiac insufficiency , include recent ( &lt; 6 month ) occurrence myocardial infarction , presence congestive cardiac insufficiency , symptomatic angor spite optimal medical care , cardiac arrhythmia require medical treatment present insufficient rhythm control , uncontrolled arterial hypertension Pregnancy breast feed Platinum resistant refractory disease Active bacterial , viral fungal infection Active gastroduodenal ulcer Parenchymal liver disease ( stage cirrhosis ) Uncontrolled diabetes mellitus Severe obstructive restrictive respiratory insufficiency Psychiatric pathology capable affect comprehension judgment faculty Tumor presence obstruction Evidence extraabdominal disease ( exception unilateral malignant pleural effusion ) extensive liver metastasis Simplified peritoneal cancer index ( sPCI ) ≥ 15</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cytoreductive surgery</keyword>
	<keyword>( H ) ipec</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Peritoneal carcinomatosis</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>